See more : PSK Inc. (319660.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of MedMen Enterprises Inc. (MMNFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedMen Enterprises Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Houston InterWeb Design, Inc. (HITD) Income Statement Analysis – Financial Results
- China Environmental Technology Holdings Limited (0646.HK) Income Statement Analysis – Financial Results
- Linus Digital Finance AG (LDF.F) Income Statement Analysis – Financial Results
- Kootenay Silver Inc. (KTN.V) Income Statement Analysis – Financial Results
- Dynasty Ceramic Public Company Limited (DCC-R.BK) Income Statement Analysis – Financial Results
MedMen Enterprises Inc. (MMNFF)
About MedMen Enterprises Inc.
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.81M | 145.07M | 157.11M | 129.96M | 39.78M | 2.67M | 20.07K | 26.65K | 20.64K | 24.92K | 19.66K | 27.66K | 18.14K | 33.60K | 36.42K | 22.18K | 20.28K | 19.34K | 30.11K | 0.00 | 305.46K |
| Cost of Revenue | 71.08M | 77.78M | 98.99M | 69.09M | 25.93M | 1.80M | 7.89K | 7.66K | 7.96K | 7.78K | 9.02K | 10.70K | 9.33K | 10.32K | 9.36K | 10.82K | 8.19K | 7.78K | 19.30K | 0.00 | 395.02K |
| Gross Profit | 69.73M | 67.29M | 58.12M | 60.88M | 13.85M | 868.14K | 12.18K | 19.00K | 12.69K | 17.14K | 10.63K | 16.96K | 8.81K | 23.28K | 27.06K | 11.36K | 12.08K | 11.56K | 10.81K | 0.00 | -89.56K |
| Gross Profit Ratio | 49.52% | 46.39% | 36.99% | 46.84% | 34.81% | 32.49% | 60.69% | 71.27% | 61.46% | 68.78% | 54.09% | 61.32% | 48.56% | 69.30% | 74.31% | 51.23% | 59.59% | 59.76% | 35.90% | 0.00% | -29.32% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 108.72M | 124.59M | 200.27M | 234.65M | 98.18M | 14.14M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 0.00 | 0.00 |
| Selling & Marketing | 3.21M | 1.11M | 10.64M | 27.55M | 7.01M | 323.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 111.93M | 125.70M | 210.92M | 262.20M | 105.20M | 14.46M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 171.76K |
| Other Expenses | 19.10M | 30.89M | 39.95M | 20.98M | 5.26M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 131.03M | 156.59M | 250.87M | 283.17M | 110.45M | 15.66M | 136.18K | 240.61K | 133.04K | 236.99K | 53.70K | 28.22K | 41.69K | 41.73K | 11.11K | 8.91K | 9.37K | 19.11K | 45.59K | 74.82K | 179.99K |
| Cost & Expenses | 202.11M | 234.37M | 349.86M | 352.26M | 136.39M | 17.46M | 144.07K | 248.26K | 140.99K | 244.77K | 62.73K | 38.92K | 51.02K | 52.05K | 20.47K | 19.73K | 17.56K | 26.90K | 64.89K | 74.82K | 575.01K |
| Interest Income | 91.59K | 649.23K | 766.04K | 701.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 43.07M | 61.37M | 49.49M | 22.82M | 16.11M | 512.44K | 135.37 | 6.53K | 2.46K | 30.07K | 35.41K | 34.97K | 35.93K | 30.44K | 37.00K | 31.38K | 29.77K | 17.16K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.74M | 34.46M | 43.71M | 23.54M | 5.15M | 1.57M | 22.82K | 6.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.33K | 0.00 | 10.08K | 0.00 | 0.00 |
| EBITDA | -35.56M | -54.84M | -149.04M | -198.75M | -91.45M | -13.22M | -124.01K | -221.61K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 219.04K | -7.55K | -24.71K | -74.82K | -269.55K |
| EBITDA Ratio | -25.26% | -37.81% | -94.86% | -152.93% | -229.87% | -494.85% | -618.00% | -831.49% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 1,080.18% | -39.05% | -82.07% | 0.00% | -88.24% |
| Operating Income | -61.30M | -89.30M | -192.75M | -222.30M | -96.60M | -14.79M | -124.01K | -228.14K | -120.35K | -219.85K | -43.07K | -11.26K | -32.88K | -18.45K | 15.95K | 2.45K | 2.72K | -7.55K | -34.79K | -74.82K | -269.55K |
| Operating Income Ratio | -43.53% | -61.56% | -122.68% | -171.05% | -242.83% | -553.54% | -618.00% | -855.98% | -582.98% | -882.08% | -219.12% | -40.73% | -181.26% | -54.90% | 43.80% | 11.04% | 13.40% | -39.05% | -115.55% | 0.00% | -88.24% |
| Total Other Income/Expenses | -114.15M | -67.40M | -328.92M | -22.30M | -11.01M | -2.91M | -18.81 | 0.00 | -2.46K | -30.07K | -35.41K | -34.97K | -35.93K | -30.44K | -37.00K | -31.38K | 186.55K | -17.16K | 360.22K | 0.00 | -1.00M |
| Income Before Tax | -175.45M | -143.61M | -515.35M | -263.23M | -110.73M | -15.38M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | 0.00 | -1.27M |
| Income Before Tax Ratio | -124.60% | -99.00% | -328.01% | -202.54% | -278.32% | -575.46% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
| Income Tax Expense | -9.90M | 1.83M | -39.60M | 13.81M | 1.54M | 43.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.77K | 0.00 | 0.00 | 75.18K | 0.00 |
| Net Income | -165.55M | -145.45M | -475.75M | -277.05M | -112.26M | -15.42M | -124.14K | -228.14K | -122.80K | -249.92K | -78.48K | -46.23K | -68.81K | -48.88K | -21.05K | -28.93K | 189.27K | -24.72K | 325.43K | -75.18K | -1.27M |
| Net Income Ratio | -117.57% | -100.26% | -302.81% | -213.17% | -282.19% | -577.07% | -618.67% | -855.98% | -594.87% | -1,002.74% | -399.26% | -167.16% | -379.31% | -145.49% | -57.81% | -130.46% | 933.37% | -127.80% | 1,080.98% | 0.00% | -416.30% |
| EPS | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
| EPS Diluted | -0.14 | -0.27 | -1.76 | -2.62 | -2.77 | -26.33 | -0.21 | -0.56 | -0.50 | -0.93 | -1.76 | -1.03 | -1.54 | -1.09 | -0.47 | -0.65 | 4.24 | -0.55 | 7.28 | -1.68 | -28.73 |
| Weighted Avg Shares Out | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
| Weighted Avg Shares Out (Dil) | 1.15B | 530.98M | 270.42M | 105.92M | 40.48M | 585.58K | 585.58K | 410.57K | 245.24K | 268.30K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.67K | 44.26K |
MedMen Announces LitHouse Farms to Manage California and Nevada Cultivation Facilities in Conjunction with Cash Flow Accretive Foundry Works Partnership
LOS ANGELES--(BUSINESS WIRE)--MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier U.S. cannabis retailer, today announced that LitHouse Farms, one of the most highly‐awarded cultivators in California, has agreed to manage cultivation and manufacturing at each...
MedMen: Cannabis MSO With Improved Hope, But Extra Risk
MedMen Enterprises continues to back substantial progress in improving the MSO business. The company still produces adjusted EBITDA losses and is far too reliant on the highly competitive California market.
MedMen Reports 55% YoY Increase In Q4 2021 Revenue, Continues To Execute Its 2.0 Growth Plan After Partnering With Tilray And Serruya Private Equity
Cannabis retailer MedMen Enterprises Inc. (CSE:MMEN) (OTCQX:MMNFF) reported its consolidated financial results Thursday for its fourth quarter and for the fiscal year ended June 26, revealing a 55.4% year-over-year and 18.5% sequential increase in revenue to $42 million in the last...
MedMen Enterprises Inc. (MMNFF) CEO Tom Lynch on Q4 2021 Results - Earnings Call Transcript
MedMen Enterprises Inc. (MMNFF) CEO Tom Lynch on Q4 2021 Results - Earnings Call Transcript
MedMen Reports 55% Year-Over-Year Quarterly Revenue Growth and Second Consecutive Quarter of Growth in Both Revenue and Retail Adjusted EBITDA
LOS ANGELES--(BUSINESS WIRE)--Fiscal Q4 and Full Year 2021 Earnings
Tilray Stockholders Approve Proposal to Increase Authorized Shares at Special Meeting
NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced that stockholders holding more than a majority of its issued and outstanding shares of...
MedMen To Announce Year Ended and Fourth Quarter Fiscal 2021 Financial Results on September 23, 2021
LOS ANGELES--(BUSINESS WIRE)--MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis retailer with operations across the United States, confirmed that it will release its financial results for the year ended and fourth quarter fiscal 2021...
Waiting For The Top Down In Cannabis (Podcast)
Waiting For The Top Down In Cannabis (Podcast)
Tilray Chairman and CEO, Irwin D. Simon, Sends Shareholder Letter Mapping out $4B Revenue Plan
NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today sent an open letter to shareholders from Irwin D. Simon, Chairman and Chief Executive Officer....
Best Cannabis Penny Stocks Under $1? 2 For Your List This Week
Pot Penny Stocks To Watch before September The post Best Cannabis Penny Stocks Under $1? 2 For Your List This Week appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.
Source: https://incomestatements.info
Category: Stock Reports